Amid the 'su­per­bug' cri­sis, a Big Phar­ma-backed fund scores a mea­ger raise for an­tibi­otics R&D. Is $140M near­ly enough?

Years af­ter Big Phar­ma aban­doned the an­tibi­otics space, a small syn­di­cate has raised $140 mil­lion to ad­dress the loom­ing threat of an­timi­cro­bial re­sis­tance — but is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA